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ABSTRACT
Accurate identification of cancer biomarkers and classification of cancer type 
and subtype from High Throughput Sequencing (HTS) data is a challenging problem 
because it requires manual processing of raw HTS data from various sequencing 
platforms, quality control, and normalization, which are both tedious and time-
consuming. Machine learning techniques for cancer class prediction and biomarker 
discovery can hasten cancer detection and significantly improve prognosis. To date, 
great research efforts have been taken for cancer biomarker identification and cancer 
class prediction. However, currently available tools and pipelines lack flexibility in data 
preprocessing, running multiple feature selection methods and learning algorithms, 
therefore, developing a freely available and easy-to-use program is strongly 
demanded by researchers. Here, we propose CancerDiscover, an integrative open-
source software pipeline that allows users to automatically and efficiently process 
large high-throughput raw datasets, normalize, and selects best performing features 
from multiple feature selection algorithms. Additionally, the integrative pipeline lets 
users apply different feature thresholds to identify cancer biomarkers and build 
various training models to distinguish different types and subtypes of cancer. The 
open-source software is available at https://github.com/HelikarLab/CancerDiscover 
and is free for use under the GPL3 license.
INTRODUCTION
Classification of a tissue sample as cancer or normal 
and among different tissue subtypes facilitates cancer 
treatment, and high-throughput techniques generate 
massive amounts of cancer data. Machine learning (ML) 
has the potential to improve such classification, and 
the traditional motivation behind ML feature selection 
algorithms is to find the optimal subset of features. 
However, no single feature selection algorithm or 
classification algorithm can provide the best set of features 
and classifiers [1]. Therefore, there is a need to develop 
a pipeline that lets users apply different feature selection 
algorithms, feature thresholds, and various classification 
algorithms to generate accurate prediction models and 
evaluation reports that distinguish cancer from normal 
samples, as well as different types and subtypes of cancer.
Remarkable efforts have been put to develop gene 
expression analysis tools and databases for cancer high-
throughput data [2–11]. Several machine learning tools 
have been developed to study cancer classification [12–
16]. However, Classifusion [14], ESVM [15], Prophet 
[16] are either not available, abandoned or not maintained. 
The available platforms require processed raw data that 
have been normalized to address various technical and 
statistical challenges such as, gene expression value 
differences within the datasets and sequencing platform 
bias. Moreover, different analysis steps have to be 
performed manually by various tools, often using different 
software platforms. These long and manual processing 
www.impactjournals.com/oncotarget/                      Oncotarget, 2018, Vol. 9, (No. 2), pp: 2565-2573
                   Research Paper
Oncotarget2566www.impactjournals.com/oncotarget
steps are not only time-consuming but also error-prone, 
making high-quality, large-scale ML analyses difficult.
To this end, we have developed CancerDiscover, 
an integrative software pipeline, which, given raw, 
bulk high-throughput data from various platforms, can 
perform quality checks, normalize the data, select the 
most important features from multiple feature selection 
algorithms, and build and evaluate different machine 
learning models in a streamlined fashion. Unlike software 
tools that require manual processing and are limited in 
feature selection and classification algorithm options (e.g., 
GenePattern [13] and Chipster [12]), CancerDiscover is 
a fully automated pipeline, while providing users with 
full control over each analysis step. CancerDiscover is 
complementary to the data repositories, data visualization, 
and the software tools such as ONCOMINE [9], INDEED 
[10] and cBioPortal [11] that support data visualization 
and analysis of differential gene expression. Herein, 
we describe the open-source software and demonstrate 
its utility and flexibility through a case study. We also 
demonstrated the utility of CancerDiscover pipeline 
using 2,175 gene expression samples from nine tissue 
types to identify tissue-specific biomarkers (gene sets) 
whose expression is characteristic of each cancer class 
and built single-tissue and multi-tissue models [17]. In 
the end, we provided the benchmarking statistics using 
CancerDiscover for datasets of varying sizes.
RESULTS AND DISCUSSION
Implementation
The purpose of CancerDiscover pipeline tool is 
to allow users to efficiently and automatically process 
large high-throughput datasets by transforming various 
raw datasets and selecting best performing features 
from multiple feature selection algorithms. The pipeline 
lets users apply different feature thresholds and various 
learning algorithms to generate multiple prediction models 
that distinguish different types and subtypes of cancer.
CancerDiscover takes raw datasets, normalizes it, 
generates WEKA [18]-native (Attribute-Relation File 
Format: ARFF) input files. The pipeline is illustrated in 
Figure 1. CancerDiscover consists of eight components: 
normalization, preliminary feature vector generation, 
preliminary data partitioning, feature selection, feature 
vector generation, data partitioning, model training 
and model testing. These components are organized 
into three scripts (masterScript_1, masterScript_2, and 
masterScript_3). In addition to Bash, the CancerDiscover 
pipeline is also implemented in SLURM (Simple Linux 
Utility for Resource Management) to make it available for 
high-performance computing clusters.
(1). Normalization: Due to the inherent differences 
among samples obtained from various studies, 
normalization and background corrections are 
required to remove or subdue bias in raw data for 
accurate models. Once raw high-throughput data is 
obtained, normalization and background corrections 
are performed to remove the technical variation 
from noisy data and background noise from signal 
intensities and generated the expression set matrix 
(for example, gene expression intensity values, etc.).
(2). Preliminary Feature Vector Generation: Next, 
the expression set matrix is used to create the master 
feature vector in the WEKA-native file format 
(ARFF).
(3). Preliminary Data Partitioning (Stratified): 
Stratified data partitioning was used by splitting the 
master feature vector into training and testing sets to 
maintain an even distribution of class distribution. 
These training sets are used to construct the models 
after feature selection has been performed in the next 
step. Later, the model’s accuracy will be assessed 
with the testing set, which had not been exposed to 
the model, giving an honest assessment of the model. 
Users of CancerDiscover can specify the size of the 
data partition of their choice in the pipeline.
(4). Feature Selection (on training data set only): Our 
pipeline offers the ability to select multiple feature 
selection algorithms. Each of these algorithms 
provides the list of ranked features that distinguish 
different types and subtypes of cancer. Users can 
choose different feature thresholds and can explore 
the relationship between the number of features 
considered by the classification algorithms and model 
accuracy. For example, the feature sets generated 
can be separated into different feature thresholds 
(including the top 1%, 10%, 33%, 66%, 100% of the 
total number of ranked features as well as the top 25, 
50 and 100 ranked features). Users can also arbitrarily 
choose these thresholds to identify the minimum 
number of features needed to achieve accurate 
classification models. For a list of available feature 
selection methods, see Supplementary File 2.
(5). Feature Vector Generation: Since the classification 
models must be built based only on the ranked 
features, new feature vectors are generated based on 
the ranked feature sets.
(6). Data Partitioning (Stratified): Once the new feature 
vectors are generated, each feature vectors file will 
undergo a second data partitioning. This partitioning 
seed value (or integer that defines the exact sequence 
of a pseudo-random number) is the same as the one 
used in the preliminary data partitioning. As such, 
each new feature vector will be split into the same 
training and testing sets as in step 3. The master 
training and testing feature vectors and the new 
training and testing feature vectors differ only in 
the number of features; the master feature vectors 
contain all of the features, whereas the newly created 
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feature vectors contain only the features that ranked 
according to different thresholds (Dimensionality 
Reduction).
(7). Model Training: CancerDiscover provides a diverse 
set of machine learning classification algorithms and 
allows the user to build models as they see fit. Each 
new training dataset from the above step undergoes 
machine learning model construction using stratified 
k-fold cross-validation to identify the optimal model.
(8). Model Testing: The model performance was assessed 
by testing its accuracy using the testing dataset that 
was kept hidden from the model. The model can also 
be used to predict the class labels for the samples 
in the unknown dataset. In the case study below, 
we illustrate the utility of the software to classify 
normal vs. cancerous tissues and adenocarcinoma vs. 
squamous carcinoma based on gene expression data.
Installation/operation
CancerDiscover software is available at https://
github.com/HelikarLab/CancerDiscover. All the 
components of the pipeline are organized into three 
scripts (namely masterScript_1, masterScript_2, and 
masterScript_3), each of which is composed of several 
scripts (PERL, AWK, SHELL, BASH, R, and SLURM). 
The detailed installation/operation of the pipeline is 
described in the Supplementary File 1. There are two 
versions of the CancerDiscover pipeline: the beginner 
version consists of bash scripts that can be run on the local 
machine and an advanced version that consists of SLURM 
(Simple Linux Utility for Resource Management) scripts 
that can be run on a high-performance computer (HPC). 
SLURM is a computational architecture used to organize 
user requests into a queue to utilize high-performance 
computing resources. Due to the sheer size of the high-
throughput data and complexity of data processing steps, 
it is recommended to use CancerDiscover on a high-
performance compute cluster. The command-line pipeline 
is compatible with Linux OS and Mac OSX.
Case study
Two kinds of ML models were generated and tested 
to illustrate the possible application of the pipeline. The 
first model was developed to classify tissue samples 
as either cancerous or normal, according to their gene 
expression patterns. Sample distributions were as follows: 
237 tumor tissue samples and 17 histologically normal 
tissue samples split evenly into testing and training data 
sets. The Quantile Normalization Method [19] was used 
to normalize the data, and the background correction was 
performed using the Robust Multichip Average (RMA) 
[20] parameter method by modifying the configuration 
file for the case study presented in the paper. Filtered 
Attribute Evaluator combined with Ranker method was 
the algorithm selected (using pipeline configuration 
file) to perform feature selection on the training dataset. 
This algorithm outputs a list of all data features ranked 
according to their utility in distinguishing the different 
Figure 1: Schematic representation of the CancerDiscover pipeline. First, raw data are normalized, background correction is 
performed, and the output is partitioned into training and testing sets. The test set is held in reserve for model testing while the training set 
undergoes a feature selection method. Feature selection provides a list of ranked attributes that are subsequently used to rebuild the training 
and testing sets. The training dataset is subsequently used to build machine learning models. Finally, the testing data set is used for model 
testing.
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classes of samples; features ranked at the top of the list 
are most useful in distinguishing cancer from normal 
samples. The plates used for this case study contain 
approximately 10,000 full-length genes corresponding 
to 12,625 probes (features). The top (0.25%, 0.5%, 1%, 
10%, 33%, 100%) ranked features, as well as additional 
feature sets containing the top (3, 6, 12, 100, 500) features 
were used for generating several models simultaneously. 
Training and testing accuracies are reported in Figure 2A-
2D. We selected RF and SVM as the machine learning 
classification algorithms for the case study.
We achieved a model training accuracy of 98.43% 
for the RF classifier using the top 0.25% (31 attributes) 
of features. Models constructed using the top 3% of 
ranked features reported an accuracy of 96.06%, while 
models using the entire list of features (100%) resulted 
in the lowest accuracy of 93.70%. Training accuracies 
for the SVM classifier were 99.21% for the models 
that used the top 3 features. Accuracy declined with the 
increasing number of features, with models that used the 
top 12 ranked features reporting an accuracy of 98.43%. 
SVM resulted in the lowest (though still relatively high) 
accuracy of 97.64% using 100 features. As few as the top 
31 features are sufficient to achieve a higher accuracy, 
using random forest classifiers, whereas top 3 features 
are sufficient to achieve a higher accuracy using support 
vector machines.
The second set of models was also bi-class; however, 
the models were developed to distinguish lung sub-types 
(adenocarcinoma vs. squamous cell carcinoma), rather 
than tumor vs. normal tissue. 211 lung adenocarcinoma 
and squamous cell carcinoma samples were evenly split 
into training and testing datasets. After feature selection, 
the list of ranked features was used to generate models 
based on different feature thresholds. Results from testing 
accuracies can be seen in Figure 2B. With the entire list 
of ranked features, the RF testing accuracy was 91.51%, 
increasing in accuracy as the percentage or number of 
ranked features decreased. The top 1% of ranked features 
(126 attributes) resulted in a model testing accuracy of 
93.40% while the top 0.25% (31 attributes) of ranked 
features resulted in testing accuracies of 95.28%. A 
similar trend was seen going from the top 500 features to 
the top 3 features. On average, SVM testing accuracies 
were more consistent and higher than those based on RF. 
The model generated with top 3 features resulted in an 
accuracy of 96.23% while using the top 6 features led 
to the accuracy of 95.28%. Using 100 features resulted 
in a testing accuracy of 97.17%. Using the top 0.25% 
and 0.5% resulted in accuracies of 96.23% and 97.17%, 
respectively, while using the top 1% and 10% features led 
to an accuracy of 98.11%. Using the top 33% of ranked 
features resulted in the highest testing accuracy of 99.06%. 
Precision, Recall, and F1-Score for the models generated 
using the top 3 features are reported in Table 1.
As shown in Table 1, we were able to achieve a 
high degree of accuracy using a small fraction of top-
ranked features (3 features). This case study illustrates 
the pipeline’s flexibility, utility, and ease-of-use in the 
generation of several models simultaneously from raw 
high-throughput data. It also highlights the customization 
allowed by CancerDiscover on the individual steps of a 
typical high-throughput data analysis pipeline, including 
the data preprocessing, normalization methods, data 
Figure 2: Model accuracies for the classification of tumor vs. normal and adenocarcinoma vs. squamous cell carcinoma: 
RF represents Random Forest classifier and SVM indicates Support Vector Machine classifier. (A) Training accuracy for 
Tumor vs. Normal model, (B) Training accuracy for Adenocarcinoma vs. Squamous Cell Carcinoma model, (C) Testing accuracy for 
Tumor vs. Normal model, (D) Testing accuracy for Adenocarcinoma vs. Squamous Cell Carcinoma model.
Oncotarget2569www.impactjournals.com/oncotarget
partitions, feature selection algorithms, classification 
algorithms, and the threshold or percentage of ranked 
features for additional analysis.
CancerDiscover benchmarking
Benchmarking was performed using 500 samples 
from Acute Myeloid Leukemia (AML) data (See 
Data Collection section for more details) to assess the 
performance of the software by running all the feature 
selection and classification algorithms. The following 
sample quantities were used; 500, 200, 100, 50 and 10. 
Each dataset was run through the pipeline performing 23 
feature selection algorithms (See Supplementary File 2 
for the list of FS methods) and classification algorithms 
to determine the required computational resources 
such as the total amount of elapsed time for each step 
of the pipeline and the total amount of elapsed time. 
These factors, mainly depend on the size of the dataset 
being processed. Benchmarking was performed using 
computational resources at the Holland Computing 
Centre of the University of Nebraska-Lincoln which has 
106 nodes, 4 CPU per nodes. Table 2 below shows the 
benchmarking results.
For the smallest set containing only ten samples, 19 
of the 23 possible feature selection algorithms completed 
processing (4 feature selection algorithms could not be 
completed due to the 10-fold cross-validation used). For 
those 19 feature selection algorithms, 585 classification 
models were generated (few of the ARFF files were empty 
for the lower feature thresholds due to the small number of 
samples). The 50-sample dataset completed 20 of the 23 
possible feature selection algorithms, thereby generating 
665 classification models. When using 100 samples, 
20 of the 23 possible feature selection algorithms were 
completed, and subsequently utilized to generate 665 
classification models. The 200-sample dataset provided 20 
of the 23 possible feature selection outputs and produced 
650 classification models. Lastly, the 500-sample dataset 
contained 20 out of the possible 23 feature selection 
outputs and generated 665 classification models. As the 
datasets grew, the time required for cancer classification 
increased linearly (Table 2).
Comparison of CancerDiscover with other 
methods
We compared the performance of CancerDiscover 
with that of the three existing methods, GenePattern [13], 
Chipster [12] and the method described in Aliferis et al. 
[21]. We used the same train and test datasets to compare 
the performance of CancerDiscover with these methods. 
Results of this analysis are summarized in Table 3, 
Supplementary Table 1 (Supplementary File 3), and 
discussed in detail below.
GenePattern [13] is a web-based platform that 
allows users to upload data and perform statistical analysis 
and class prediction. Due to the nature of the data used in 
this study, only SVM classification suite was used to draw 
comparisons between CancerDiscover and GenePattern. 
Because GenePattern could not perform normalization 
and background correction for the given datasets, we 
used the data normalized by the CancerDiscover pipeline 
(using RMA method) and provided the normalized data 
to the SVM classification module of GenePattern. The 
input data contained all probes as GenePattern did not 
provide feature selection options. ML classification 
models were generated using the training data with 
Table 1: Accuracies of random forest models using top 3 features
Training model Precision Recall F1-Score
Tumor vs. normal 98.3 98.3 98.3
Adeno vs. squamous 97.9 98.9 98.4
Table 2: Benchmarking results
Samples Feature selection methods
Models 
generated
Normalization
(Elapsed Time)
Feature selection
(Elapsed Time)
Model train & test
(Elapsed Time) Total
500 20 665 2:05:32 21:45:59 8:05:32 31:57:03
200 20 650 0:52:31 14:16:55 4:49:33 19:58:59
100 20 665 0:26:56 13:31:22 3:12:30 17:00:48
50 20 665 0:16:48 12:06:42 2:58:56 15:12:26
10 19 585 0:07:03 10:05:17 2:14:05 12:26:25
All the datasets contain 54,675 features, and 2 CPUs were used for the analysis.
Elapsed time refers to the amount of real-time spent processing that function.
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accuracies of 98.43% for the Tumor vs. Normal model, 
and 99.06% for the Adenocarcinoma vs. Squamous Cell 
Carcinoma model. These higher accuracies could also 
be due to the normalization and background correction 
performed by the CancerDiscover pipeline. Of all the 
three compared software tools, GenePattern’s accuracies 
are most similar to the ones produced by CancerDiscover 
– 99.21% and 99.06%, respectively. All probes were 
utilized in the model building since feature selection could 
not be performed using GenePattern. On the other hand, 
CancerDiscover was able to achieve similar accuracy by 
using as few as three probes (See Supplementary Table 
1 in Supplementary File 3). Finally, CancerDiscover 
differs from the proprietary GenePattern by the fact that 
CancerDiscover is open-source; as such, its methodologies 
are transparent and reproducible, and the community can 
further expand the software.
Chipster is developed based on a client-server 
architecture. Data is imported at the client side, while 
all processing is performed on the server side using 
R programming. It requires that all data need to be 
transferred between client and server for each analysis 
step which can be very time-consuming if the datasets 
are large [22]. Chipster was not able to successfully 
perform a classification when we provided the dataset 
containing all probes. As a result, feature selection was 
performed artificially; that is, the datasets provided to 
Chipster contained only those probes selected by our 
CancerDiscover feature selection method; thus, datasets 
provided included the top 3, 6, 12, 100, or 500 probes. 
Raw data in the form of CEL files were normalized 
(RMA normalization) by Chipster. The accuracy using top 
3 probes for the Tumor vs. Normal model was 97.63%, 
whereas, for the Adenocarcinoma vs. Squamous Cell 
Carcinoma model was 98.82%, ranking 3rd for the accuracy 
assessment (See Supplementary Table 1 in Supplementary 
File 3). These accuracy assessments for the CancerDiscover 
are better than the results provided by Chipster.
Data used in this paper were also analyzed 
independently in Aliferis et al. [21], using two feature 
selection algorithms: Recursive Feature Elimination 
and Univariate Association Filtering. These algorithms 
identified 6 and 100 features, respectively, as significant 
for cancer vs. normal classification, and 12 and 500 
features, respectively, for adenocarcinoma vs. squamous 
cell carcinoma classification. Aliferis et al. reported 
average accuracies across classification algorithms: 
94.97% for cancer vs. normal model, and 96.83% for 
the squamous carcinoma vs. adenocarcinoma model. 
In comparison, CancerDiscover resulted in 99.21% 
accuracy for cancer vs. normal model, and 99.06% for 
the adenocarcinoma vs. squamous cell carcinoma model, 
while using only three features. In the context of these 
data, CancerDiscover was more accurate, while using less 
information than that of Aliferis et al.
These results demonstrate that the CancerDiscover 
method is complementary to some of the existing methods, 
such as GenePattern, Chipster, and Aliferis et al. methods, 
and that it is also suitable for accurate classification of 
other types of cancer types and subtypes. Although the 
classification accuracy of CancerDiscover was marginally 
higher than that of the compared methods, the strengths of 
CancerDiscover lie in its streamlined nature that enables 
users to begin with raw data and proceed to build machine 
learning models within a complete pipeline. Another 
strength of CancerDiscover is that it is flexible, allowing 
users to utilize various methodologies within the platform, 
and further extend the software as a whole due to its open-
source nature.
In conclusion, we have developed a comprehensive, 
integrative, open-source, and freely available pipeline, 
CancerDiscover, which enables researchers to automate 
the processing and analysis of high-throughput data 
with the objective of both identifying cancer biomarkers 
and classifying cancer and normal tissue samples 
(including cancer sub-types). Herein, we showcased the 
pipeline’s flexibility, utility, and ease-of-use in generating 
multiple prediction models simultaneously from raw 
high-throughput data. CancerDiscover allows users to 
customize each step of the pipeline, preprocessing raw 
data, selecting normalization methods, data partitions, 
feature selection algorithms, and classification algorithms 
for additional analysis. The CancerDiscover pipeline was 
able to identify an optimal number of top-ranked features 
and accurately classify the sample data into its classes. 
Benchmarking demonstrated the high performance of the 
Table 3: Comparisons of machine learning classification components
Tool Components CancerDiscover GenePattern Chipster Aliferis
Normalization ü - ü -
Background correction ü - - -
Partitioning ü - - -
Feature selection ü - - ü
Modeling ü ü ü ü
This table highlights the capabilities of tools for performing different functions necessary to generate ML models.
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pipeline across datasets of varying sizes. Researchers can 
now utilize CancerDiscover for diverse projects, including 
biomarker identification, and tissue classification 
without extensive technical knowledge while retaining 
significant flexibility. Another great advantage to the 
biomedical community is that unlike GenePattern and 
Chipster, CancerDiscover is open-source and freely 
available and written in a modular fashion which opens 
an array of opportunities for users to tweak the software 
themselves for their needs, adding more algorithms as 
it becomes available. Next, we will make our efforts 
to develop graphical user interface and web server for 
CancerDiscover with additional functionalities such as 
querying, searching and downloading datasets from the 
public repositories and data visualization of the outputs.
MATERIALS AND METHODS
The presented integrative pipeline consists of 
existing open-source software tools and utilizes publicly 
available datasets and various performance metrics.
Data collection
For the case study, lung cancer (tumor vs. 
normal and adenocarcinoma vs. squamous carcinoma) 
microarray gene expression data were collected from 
the Broad Institute Cancer Program Legacy Publication 
Resources database [23]. 237 tumor tissue samples and 
17 histologically normal tissue samples, and 211 lung 
adenocarcinoma and squamous cell carcinoma samples 
were used. The plate used was Human Genome U95A 
oligonucleotide probe arrays, containing 12,625 probes. 
Benchmarking was performed using 500 samples of Acute 
Myeloid Leukemia (AML) and normal blood sample 
expression data downloaded from NCBI (GSE6891, 
GSE2677, GSE43346, GSE63270) [HG-U133_Plus_2] 
Human Genome U133 Plus 2.0 Array, containing 54,675 
probes.
Normalization and background correction
Normalization and preprocessing are essential 
steps for the analysis of high-throughput data. The Affy 
R module 1.54 [24] from Bioconductor package (https://
bioconductor.org/packages/release/bioc/html/affy.html) 
was used to remove the technical variation from noisy data 
and background noise from signal intensities. This step is 
crucial for analyzing large amounts of data which have 
been compiled from different experimental settings where, 
individual data files are processed to remove sample bias 
from the data, which could otherwise introduce a bias in 
the model. Affy R package provides multiple methods for 
normalization and background correction, which can be 
utilized within CancerDiscover using programmatic flags. 
For the case study given above, quantile normalization 
[25] and robust multichip average (RMA) [20] were used 
for normalization and background correction, respectively.
Machine learning algorithms and framework
Though the pipeline supports the diverse set of 
machine learning classifiers, we used Support Vector 
Machines (SVMs) and Random Forests to construct 
the models for the case study. These machine-learning 
methods were chosen because of their extensive and 
successful applications to datasets from genomic 
and proteomic domains [26, 27]. Some of the cancer 
classification tasks were binary (two classes), and the 
others were multiclass (more than two classes). Though 
SVMs are designed for binary classification, they can 
also be used for multiclass classification by a one-versus-
rest approach [28]. The one-versus-rest approach for 
classification is known to be among the best-performing 
methods for multi-category classification for microarray 
gene expression data [29]. Models were also constructed 
using Random Forests (RF), which can solve multi-
category problems natively through a direct application 
[30]. Waikato Environment for Knowledge Analysis 
(WEKA 3-6-11) [18] is a machine learning software 
environment that serves as a platform for clustering and 
classification of high-throughput data.
Performance measure
Accuracy was defined as the overall ability of 
models to predict testing data correctly. Reported 
measures included the numbers of true positives (TP), 
true negatives (TN), false positives (FP), and false 
negatives (FN). A true-positive count is the number of 
samples in a dataset which were correctly categorized 
into classes. A false-positive count is the number of 
samples in a dataset which were sorted into the wrong 
category. A true negative count represents the number of 
samples which were not classified into a class to which 
they do not belong, and false negatives are samples which 
are not classified into the class to which they do belong. 
Accuracy, Sensitivity (or Recall), Specificity, Precision, 
F1-Score are derived from the measures mentioned 
above as follows: accuracy is the ratio of correctly 
predicted samples to the total number of samples. 
Sensitivity is the proportion of true positives that are 
predicted as positives. Specificity is the proportion of 
true negatives which are predicted as negatives, and 
Precision is the ratio of true positives to the total number 
of true negatives and true positives. Lastly, F1-score is 
defined as the harmonic mean of Precision and Recall 
and is calculated by first multiplying precision and recall 
values, then dividing the resulting value by the total of 
precision and recall, and finally, multiplying the result 
by two. The Accuracy, Sensitivity, Specificity, Precision, 
and F1-Score are given by:
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Model selection and accuracy estimation
The pipeline offers the flexibility to choose any 
k-fold cross-validation for model selection and accuracy 
estimation. In the case study, we used stratified 10-fold 
cross-validation [27, 29]. This technique separates data 
into ten parts and uses nine parts for the model generation 
while predictions are generated and evaluated by using 
the one part. This step is subsequently repeated ten times, 
such that each part (internal test set) is tested against the 
other nine parts (internal train set). After the 10-fold cross-
validation, the average performance of all of the folds is 
used as an unbiased estimate of the performance of model 
training.
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